Sean Visit 1: A 65-year-old man with progressive memory loss

Title:

Sean Visit 1: A 65-year-old man with progressive memory loss

Topic: Neurology
Relevant Terms: Alzheimer's Disease, Mild Cognitive Impairment
Primary Audience: This activity has been designed to meet the educational needs of neurologists and physicians in both primary care and specialty practice that diagnose and treat Alzheimer's Disease.
Launch Date: 06-Dec-12
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Diagnosing progressive memory loss

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Identify three potential tests that could be used for better identification of dementia associated with Alzheimer's disease (AD) in order to improve the early diagnosis.
  2. Discuss why biomarker screening is important for AD diagnosis and management.
  3. Develop individualized treatment plans in order to improve short- and long-term outcomes for patients with AD.
  4. Evaluate two novel classes of medication that are in development and explain their proposed mechanisms of action.

    Faculty

    Gad A. Marshall, MD
    Assistant Professor of Neurology
    Harvard Medical School
    Associate Medical Director of Clinical Trials; Associate Neurologist
    Center for Alzheimer Research & Treatment
    Brigham and Women's Hospital
    Assistant in Neurology
    Massachusetts General Hospital
    Boston, MA
    Scott M. McGinnis, MD
    Instructor, Neurology
    Harvard Medical School
    Associate Neurologist (BLOH), Assistant in Neurology (MGH)
    Brigham and Women's Hospital, Massachusetts General Hospital
    Boston, MA
    PROGRAM OVERVIEW:
    It is estimated that four million Americans suffer from Alzheimer's Disease (AD) or a related form of dementia. Nearly 10% of all people over the age of 65, and up to half of those over the age of 85, are estimated to have AD or dementia. Unfortunately these numbers are increasing as the population of elderly increases. By 2050, an estimated 14 million Americans will have AD.
     
    The emotional and financial toll on individuals suffering with AD or a related form of dementia, and on their families, is significant. Many people living with AD reside with family until the most advanced stages of the disease become evident, at which time many family members find that they need to place their elderly relatives into a nursing home. It is estimated that the average per patient cost for nursing home care is around $42,000/year.
     
    In recent years there have been significant advances in the understanding of AD's pathogenesis, methods to diagnose AD, and treatment options. While disease-modifying therapies are still under development and immunotherapy may be a viable treatment option in the near future, at present, only symptomatic treatments are available. Early diagnosis, early treatment and awareness of "pipeline" (in development or under investigation) therapies are essential for optimal management of AD.

    CME ADVISORY COMMITTEE:
     
    Course Director/Course Reviewer
    Katherine Galluzzi, DO, CMD, FACOFP dist.
    Professor and Chairperson, Department of Geriatrics
    Philadelphia College of Osteopathic Medicine
    Attending Physician, Family Medicine
    Tenet Roxborough Memorial Hospital
    Philadelphia, PA
     
    PLANNING COMMITTEE:
     
    Joshua Kilbridge
    President
    Kilbridge Associates
    Healthcare Communications
     
    Kelly Kraines
    General Manager
    Med Learning Group
     
    R. Michelle Tyner, MS
    Associate Director, Business Development
    Senior Grant Writer
    Med Learning Group
     
    Christopher Cahill
    Associate Director, Planning and Projects
    Med Learning Group

    DISCLOSURE POLICY STATEMENT:
    In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
     
    DISCLOSURE OF CONFLICTS OF INTEREST:
     
    Gad A. Marshall, MD
    Disclosure: Dr. Marshall receives research funding from Pfizer Inc., and Janssen Alzheimer Immunotherapy. Dr. Marshall also receives consulting fees from Grifols.
     
    Scott A. McGinnis, MD
    Disclosure: Dr. McGinnis receives research funding from Allon Therapeutics Inc., Pfizer Inc., Janssen Therapeutics, and Medivation Inc.
     
    Katherine Galluzzi, DO, CMD, FACOFP dist.
    Disclosure: Dr. Galluzzi has no relevant financial relationships to disclose.
     
     
    Planning Committee
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    Joshua Kilbridge of Kilbridge Associates has no relevant financial relationships to disclose.
     
    Kelly Kraines of Med Learning Group has no relevant financial relationships to disclose.
     
    R. Michelle Tyner, MS of Med Learning Group has no relevant financial relationships to disclose.
     
    Christopher Cahill, of Med Learning Group has no relevant financial relationships to disclose.
     
     
    ACCREDITATION STATEMENT:
    Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    This CME activity was planned and produced in accordance with the ACCME Essentials.
    For CME questions, please contact: Med Learning Group at info@medlearninggroup.com
    Contact this CME provider for privacy and confidentiality policy statement information at:
    http://www.medlearninggroup.com/?page_id=865


    CREDIT DESIGNATION STATEMENT:
    Med Learning Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    TO OBTAIN CME CREDITS:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit.
    • You must score 70% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
       
    DISCLOSURE OF UNLABELED USE:
    Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
     
    COURSE VIEWING REQUIREMENTS:
    Google Chrome for Windows, Mac, or Linux
    Internet Explorer 7.0+ for Windows
    Mozilla 1.4+ for Windows, Mac, or Linux
    Firefox 3.5+ for Windows, Mac, or Linux
    Safari 4.0+ for Mac

    MEDIUM: Internet
     
    ACKNOWLEDGEMENT:
    This activity is sponsored by Med Learning Group.


                                     
    This activity is supported by an educational grant from Lilly USA, LLC.



    If you have any questions regarding this activity, send an email to info@medlearninggroup.com.
     
    This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields.  
     
    Copyright © 2012 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.